Symptoms are a reason to investigate
It is reasonable to seek help when your energy or physical capacity changes. The difficult part is that broad symptoms do not identify a single cause. An online checklist that labels several common experiences as signs of low growth hormone may create more certainty than the evidence supports.
The useful first conversation is about the symptom: when it began, how it affects your life, what else changed, and what evaluation has already occurred. That gives a clinician something more informative than a yes-or-no wellness score.
A treatment recommendation should follow that assessment. When the proposed medication is chosen before the diagnosis is explained, ask the clinician to walk through the reasoning and any other plausible explanations for the problem.
It can help to write down one or two concrete examples before the appointment: a usual walk now feels difficult, or fatigue is interfering with work. These examples communicate impact without presuming its cause. Also describe whether the problem is stable or worsening. A symptom-focused history gives the clinician a better starting point than selecting a hormone panel simply because it appears in a wellness package.
Medical history changes how tests are interpreted
The Endocrine Society guideline describes adult growth hormone deficiency as a condition requiring a structured evaluation. A history suggesting pituitary disease is different from an isolated concern about normal aging.
Bring records of pituitary surgery or other relevant treatment, childhood hormone diagnoses, and any existing endocrine care. The clinician can decide which information changes the likelihood of deficiency and whether specialist testing is appropriate.
This is why a laboratory result cannot be interpreted entirely apart from the person. The same number may lead to different next steps depending on the clinical setting. That is not inconsistency; it reflects that tests answer questions within a diagnostic process.
IGF-1 is useful, but it is not the whole diagnosis
IGF-1 is often included in an evaluation of the growth hormone system. It should be read using the laboratory’s reference information and the clinical context. A value near the lower end is not a self-contained prescription recommendation.
Research comparing six IGF-I assays demonstrates that measurement method matters. Comparing your value with an influencer’s target or a friend’s result from another laboratory can therefore be misleading.
Ask what the result supports, what it cannot exclude, and what further evidence would change the assessment. Our guide to IGF-1 reference ranges goes deeper into age, assay differences, and why an “optimal” target needs a clinical justification.
Why stimulation testing may be needed
The Endocrine Society states that confirmation through stimulation testing is usually required, with exceptions in specific established circumstances. The purpose is to evaluate a response under a defined diagnostic protocol rather than treating an isolated hormone snapshot as decisive.
The choice and interpretation of a test belong with the clinician overseeing the evaluation. Ask why the chosen test fits your history, what preparation is needed, and who will interpret the result. Do not attempt to reproduce a diagnostic challenge with a purchased peptide.
A response to a medication prescribed for wellness does not retroactively prove that you had deficiency. Likewise, feeling better during treatment is worth discussing but cannot substitute for the evidence needed to establish the original diagnosis.
Leave the appointment with a clear explanation
A useful consultation should leave you knowing whether deficiency is confirmed, suspected, or unlikely—and why. If uncertainty remains, the next step should be explicit. You should not have to infer the diagnosis from a subscription recommendation.
If a hormone disorder is confirmed, ask which treatments are supported for that diagnosis and how their evidence differs from sermorelin wellness claims. Growth hormone replacement and stimulation of growth hormone release are distinct approaches; see sermorelin versus HGH.
If the evaluation points elsewhere, that is also progress. It creates an opportunity to address the actual source of symptoms. The purpose of testing is to guide useful care, not to find a number that justifies a product already selected.
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.